BTL Industries recently concluded its North American Sales Meeting, bringing together more than 350 participants from across the United States and Canada. The meeting reflected a year of strong execution in the region and aligned the organization around priorities for 2026.

During the meeting, BTL confirmed that it has surpassed $850 million in global revenue, underpinned by robust and sustained growth in North America. Regional performance was driven by strong demand across wellness, longevity, and aesthetics, as well as mental health, functional therapy and rehabilitation, highlighting the breadth and maturity of BTL's established portfolio in the North American market.

To support this trajectory, BTL continues to expand its North American organization, selectively adding talent across commercial, clinical, and operational functions. This measured growth in headcount reflects rising market demand and supports continued expansion across core application areas.

As part of its 2026 initiatives, BTL announced that it has received regulatory clearance in Canada for its dry eye treatment solution, marking entry into ophthalmology as a new specialty segment within the North American market. In parallel, 2026 also marks the commercial launch of EMVITAL, a new functional laser platform powered by advanced TriHIL™ technology. EMVITAL is designed to deliver precise, hands-free, non-invasive tissue heating to support relief from muscle and joint discomfort and enhance functional comfort, and has also received Health Canada license for inflammation-related indications.

"Our results in North America reflect the strength of our core portfolio, disciplined execution, and our ability to scale effectively across multiple clinical segments," said David Chmel, CEO of BTL North America. "Looking ahead, our growth outlook for 2026 is anchored by continued innovation, expanding clinical adoption, and targeted investment in our people, alongside new regulatory clearances and the launch of EMVITAL."

About BTL

Founded in 1993, BTL is a global leader in medical device innovation, providing advanced solutions across aesthetic medicine, dermatology, plastic surgery, rehabilitation, orthopaedics, joint and spine care, dentistry, primary care, OB/GYN, and more. With more than 200 patents and over 600 in-house engineers, BTL leverages science and technology to advance non-invasive and therapeutic medical treatments worldwide. Its product portfolio includes EMFACE®, EXION®, EMSCULPT NEO®, EXOMIND®, EMSELLA®, EMVITAL®, and others.

Media Contact:
Samantha Slaven-Bick
samantha@samanthaslaven.com 

BTL Group, a global leader in medical technologies, today announced the successful resolution of multiple patent infringement proceedings against Lexter Microelectronic Engineering Systems S.L. ("Lexter"), the manufacturer of the WonderFace device.

The settlement follows patent infringement litigation initiated by BTL in multiple jurisdictions to protect its proprietary EMFACE® technology. As a result of the settlement, Lexter has agreed to cease the manufacture, global marketing and distribution, and use of facial treatment technologies and associated disposables that simultaneously combine radiofrequency and electrical muscle stimulation.

As a leader in medical innovation, BTL owns a robust international patent portfolio protecting fundamental aspects of energy-based technologies.

"The global and definitive impact of this settlement testifies to our dedication to defending BTL's intellectual property and protecting the investments of our customers," said Tomas Schwarz, CEO of the BTL Group.

For more information about EMFACE®, visit www.emface.com.

About BTL
Founded in 1993, BTL is a global leader in medical device innovation, providing advanced solutions across aesthetic medicine, dermatology, plastic surgery, rehabilitation, orthopaedics, joint and spine care, dentistry, primary care, and OB/GYN. With more than 200 patents and over 600 in-house engineers, BTL leverages science and technology to advance non-invasive and therapeutic medical treatments worldwide. Its product portfolio includes EMFACE®, EXION®, EMSCULPT NEO®, EXOMIND®, EMSELLA®, EMVITAL®, and others.

BTL, a global leader in medical technologies, proudly announces that its flagship device, EMSCULPT NEO, played a key role in astronaut preparation ahead of a historic spaceflight. As a result of the cooperation between BTL Hungary and HUNOR (Hungarian To Orbit) program, EMSCULPT NEO was incorporated into Hungarian research astronaut Tibor Kapu's intensive pre-flight training program to prepare for his upcoming mission aboard the International Space Station (ISS).

"Studies show astronauts lose up to 30% of muscle mass in orbit, depending on the duration of the mission. EMSCULPT NEO has been an essential part of physical conditioning and rehabilitation, helping us maximize both muscle performance and recovery," said Dr. Nóra Sydó, a cardiologist and sports medicine specialist from Semmelweis University, Budapest, who led the astronaut training team.

EMSCULPT NEO was part of a comprehensive conditioning protocol designed to improve endurance, strength, balance, and recovery. "This technology gave us results beyond traditional training. Medical tests showed muscle hypertrophy, improved body composition, and increased cardiopulmonary fitness," added Dr. Nóra Sydó, who also serves as team doctor for Hungary's Olympic swimming team and several national sports clubs.

Developed by BTL, EMSCULPT NEO is a patented muscle-stimulation technology. It is a leading solution used by thousands of medical practices across multiple specialties, ranging from aesthetics and functional medicine to specialized medical centers.

"This is a proud moment. Our mission is to improve patients' lives through innovation. The fact that our technologies have supported humans on their way to space is further testimony to the positive impact our devices have on society," commented Tomas Schwarz, CEO of the BTL Enterprise Group.

While involvement in astronaut training is a major milestone, the benefits of the device extend far beyond. "Whether it's an astronaut, an Olympic champion, or a patient facing muscle loss, EMSCULPT NEO can be an effective, safe, and non-invasive complementary solution to preserve and enhance muscle function," concluded Dr. Nóra Sydó, highlighting the possible role of this technology in both elite sports and everyday patient care.

About BTL:

Founded in 1993, BTL is a global leader in medical devices, providing innovative solutions in dermatology, plastic surgery, med spas, orthopedics, joint and spine care, rehabilitation, dentistry, primary care, OB/GYN, and more. With 200+ patents and over 600 in-house engineers, BTL leverages technology and science to advance medical treatments. Its product portfolio includes EMSCULPT NEO^®, EMFACE^®, EXION^®, EXOMIND™, EMSELLA^®, and others.

In a powerful show of appreciation for the individuals who run toward danger when the world calls, BTL Industries is proud to announce the launch of its latest BTL Cares initiative — a nationwide campaign to support the mental and physical health of firefighters.

Through partnerships with select clinics in high-risk wildfire regions, BTL will offer complimentary Exomind™ and Emsculpt Neo® treatments to firefighters. These cutting-edge technologies address  two of the most critical wellness challenges facing first responders today: mental health and soft-tissue injury recovery.

"We believe that even the strongest deserve support," said John Ferris, VP of Marketing. "This is about showing up for those who show up for us every single day."

A Human Crisis Behind the Heroism

According to national data, up to 30% of firefighters experience behavioral health issues — often worsened by physical injury, lack of recovery time, and repeated trauma exposure. Yet, many remain reluctant to seek help.

BTL's Firefighter Initiative aims to change that by offering a science-rooted, stigma-free path to healing. With these non-invasive technologies, firefighters can receive treatments that support mental health and physical recovery — all without medication, surgery, or downtime.

Why Exomind and Emsculpt Neo?

Exomind, designed for the treatment of depression, employs patented ExoTMS™ technology to comfortably stimulate key areas of the brain involved in emotional regulation and mood related disorders.

Emsculpt Neo delivers high-intensity focused electromagnetic energy to strengthen muscles and accelerate post-surgical or post-injury rehabilitation while increasing range of motion and mobility.

Together, they form a comprehensive wellness option for first responders who give their all — often at great personal cost.

A National Call to Action

BTL invites medical providers, community leaders, and the media to join in amplifying the message: "Heroes Deserve Healing." Participating clinics will be recognized as Official BTL Cares Partners, complete with campaign materials and community engagement tools.

For more information on how to support or participate in the BTL Cares Firefighter Initiative, visit BodybyBTL.com

About BTL:
Founded in 1993, BTL is a global leader in medical devices, providing innovative solutions in dermatology, plastic surgery, med spas, orthopedics, joint and spine care, rehabilitation, dentistry, primary care, OB/GYN, and more. With 200+ patents and over 500 in-house engineers, BTL leverages technology and science to advance medical treatments. Its product portfolio includes, EMSCULPT NEO^®, EMFACE^®, EXION™, EXOMIND™, EMSELLA^®, and others.

Media Contact:
Samantha Slaven-Bick
samantha@samanthaslaven.com 

BTL Industries, a global leader in medical and wellness technologies, has expanded the FDA-cleared applications of its EMFACE® platform with a new indication for the treatment of temporomandibular joint (TMJ) dysfunction.

EMFACE® is now cleared by the FDA for the relief of symptoms associated with muscle spasm, treatment of TMJ dysfunction and associated pain, muscle re-education, increased local blood flow, and the maintenance or improvement of mandibular range of motion.

Developed through years of research and engineering, EMFACE combines synchronized radiofrequency and HIFES® technology for facial muscle stimulation, delivering relief without surgery, injections, or medication.

"EMFACE is an established technology platform with multiple FDA-cleared uses," said David Chmel, CEO of BTL Industries. "This new indication allows dental, oral health, and wellness providers to address TMJ dysfunction within its approved uses, expanding the benefits of EMFACE to more patients."

"TMJ dysfunction impacts more than the jaw — it affects quality of life," said Shireen Dhanani, DMD, Leesburg, FL. "With EMFACE, we can now offer an accessible, non-invasive option that not only helps patients find relief and functional improvement, but also expands the scope of dental care."

BTL continues to redefine what's possible in facial care and wellness, bringing science-backed technologies like EMFACE into new areas of medicine to improve lives and advance patient care worldwide.

For more information about EMFACE, visit www.emface.com.

About BTL Industries

Founded in 1993, BTL is a global leader in medical devices, providing innovative solutions in dermatology, plastic surgery, med spas, orthopedics, joint and spine care, rehabilitation, dentistry, primary care, OB/GYN, and more. Operating in over 90 countries, BTL holds more than 200 patents and employs over 500 R&D engineers dedicated to advancing medical treatments through technology and science. Its product portfolio includes EMSCULPT NEO®, EMFACE®, EXION™, EXOMIND™, EMSELLA®, and others.

Media Contact: samantha@samanthaslaven.com

BTL, the global leader in aesthetic and wellness technology, proudly announces the 6th annual National Emsculpt Week, taking place May 18–24, 2025. This year's celebration is bigger than ever. It combines provider recognition, real patient transformation, and community connection for an unforgettable week.

National Emsculpt Week spotlights the providers and patients who are embracing stronger bodies, functional wellness, and vibrant aging through Emsculpt^® and Emsculpt NEO^®. In 2025, BTL is taking things up a notch with a brand-new twist: a nationwide sweepstakes that will award free Emsculpt treatments to patients across the country. It's an exciting opportunity for people to jumpstart their wellness journeys and experience Emsculpt's muscle-building, confidence-boosting power firsthand.

The heart of the celebration is a national digital competition, offering exciting prizes for the most engaging provider posts across North America. Practices will post photos, reels, or stories showing their teams, patients, or favorite Emsculpt success moments. The most engaging and inspiring entries will win major prizes — including Emsculpt device applicators and the coveted Exion™ system with choice of applicator.

"This is more than just a celebration - it's a movement," said John Ferris, VP of Marketing at BTL. "By launching a national sweepstakes and spotlighting the incredible work of our providers, we're expanding access and empowering people to feel strong in their own skin. Emsculpt Week 2025 is about transformation, connection, and celebrating what's possible."

Since its debut in 2018, Emsculpt has led the category as the first and only non-invasive technology to use HIFEM^® to build muscle and sculpt the body. In 2020, the introduction of synchronized radiofrequency with Emsculpt NEO pushed results even further — delivering an average of 30% fat reduction and 25% more muscle in treated areas, with over 4 million treatments performed globally.

In 2024, BTL took the Emsculpt brand even further and introduced the next wellness revolution: The Functional Wellness. These new treatment protocols mark a major advancement in how the technology not only sculpts the body but also supports the patients with their day-to-day life — going beyond aesthetics to address mobility, flexibility, strength, muscle atrophy, range of motion, and expedited rehabilitation. A smarter, more complete approach to helping patients not just look better, but move and feel better too.

Whether you're a provider ready to share your success or a patient ready to experience what's next, National Emsculpt Week 2025 is your moment.

Learn more at www.bodybybtl.com.

About BTL:
Founded in 1993, BTL is a global leader in medical devices, providing innovative solutions in dermatology, plastic surgery, med spas, orthopedics, joint and spine care, rehabilitation, dentistry, primary care, OB/GYN, and more. With 200+ patents and over 500 in-house engineers, BTL leverages technology and science to advance medical treatments. Its product portfolio includes , EMSCULPT NEO^®, EMFACE^®, EXION™, EXOMIND™, EMSELLA^®, and others.

Media Contact: samantha@samanthaslaven.com